Asset Details
Do you wish to reserve the book?
Increasing psychopharmacology clinical trial success rates with digital measures and biomarkers: Future methods
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Increasing psychopharmacology clinical trial success rates with digital measures and biomarkers: Future methods
Do you wish to request the book?
Increasing psychopharmacology clinical trial success rates with digital measures and biomarkers: Future methods
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Increasing psychopharmacology clinical trial success rates with digital measures and biomarkers: Future methods
2024
Overview
Psychiatric trials have some of the lowest success rates across therapeutic areas, resulting in decreased investment in psychopharmacological drug development even as the need for more effective treatments grows. Digital measures and digital biomarkers (DBMs) provide one potential avenue for ameliorating three of the largest problems impeding clinical trial success in psychiatry: diagnostic heterogeneity, endpoint subjectivity, and high placebo response rates. First, DBMs may address heterogeneity and comorbidity in psychiatric nosology by identifying predictive DBMs of treatment response via the targeting of drugs to psychiatric subtypes. Second, DBMs can provide objective measures of physiology and behavior that when grounded in meaningful aspects of health (MAH) could support use for regulatory decision-making. By objectively and continuously measuring aspects of a patient’s disease that the patient wants to improve or prevent from getting worse, DBMs might provide clinical trial endpoints that are more sensitive to treatment effects as compared to traditional clinician-reported outcomes. Lastly, DBMs could help address challenges surrounding high placebo response rates. Development of predictive DBMs of placebo response may allow for improved enrichment study designs to reduce placebo response. Objective digital measures may also be more robust against the placebo effect and offer an improved study endpoint alternative. Successful deployment of DBMs to address the historical challenges facing psychiatric drug trials will require close collaboration between industry, academic, and regulatory partners.
Publisher
Nature Publishing Group
Subject
